Bioanalysis is one of those functions nobody thinks about until it goes wrong, and then it becomes the only thing anyone thinks about. The lab that measures your drug in blood, quantifies its effect, and detects anti-drug antibodies produces the data your entire pharmacokinetic and safety story rests on. If that data is unreliable, the consequences ripple through your program. The right bioanalytical lab has proven experience with your specific molecule type and matrix, robust validated methods, genuine regulatory compliance, and the responsiveness to fix problems fast. Here is how to choose one.
Know what you actually need
Bioanalysis is not one service. You may need small molecule quantification, typically by mass spectrometry, which is well established but demanding on method sensitivity and matrix effects. You may need large molecule bioanalysis for a biologic, which relies on different techniques and brings its own complexities. You may need immunogenicity testing to detect anti-drug antibodies, which is required for biologics and is methodologically tricky. You may need biomarker assays, which often lack established methods and require development. And your work may be regulated, requiring formal good laboratory practice compliance, or exploratory. Being clear which of these you need, and at what regulatory standard, is the necessary first step, because labs differ enormously in what they do well.
What to evaluate
- Relevant molecule and matrix experience. Has the lab worked with molecules like yours, in the biological matrices you need? A lab excellent at small molecule mass spectrometry may be weak at complex biologic assays, and vice versa.
- Method development and validation capability. Can they develop a robust method if none exists, and validate it properly to the required standard? This is where many programs stumble.
- Regulatory compliance. Do they operate to the standard your study demands, with a clean inspection history? Data that cannot support a regulatory filing is worthless.
- Capacity and turnaround. Can they handle your sample volume on your timeline? Bioanalysis is often on the critical path, and delays here delay everything.
- Data quality systems. How do they ensure integrity, handle deviations, and document everything? Regulators scrutinize this closely.
Questions worth asking
Ask about their specific experience with your molecule type and matrix, with examples. Ask how they would approach method development and validation for your assay, and gauge whether the answer is thoughtful or generic. Ask about their regulatory compliance status and inspection history directly. Ask about realistic turnaround times and what happens if your sample volume spikes. Ask how they handle failed runs, out-of-specification results, and deviations, because how a lab responds to problems tells you far more than how they perform when everything works. And ask who your point of contact will be and how quickly they respond, since bioanalysis problems are urgent.
Red flags
Be cautious of labs that cannot demonstrate relevant experience with your specific molecule type, since bioanalysis expertise does not transfer easily across modalities. Treat vagueness about regulatory compliance or inspection history as serious. Be wary of unrealistic turnaround promises, which often mean corners will be cut. Watch for poor communication during the sales process, since a lab that is slow to respond when winning your business will be slower once they have it. And be skeptical of labs that seem to underestimate the difficulty of your assay, because confident dismissal of a genuinely hard analytical problem usually signals inexperience rather than expertise.
The bottom line
Your bioanalytical lab produces the data your program’s pharmacokinetic, pharmacodynamic, and safety conclusions depend on, which makes it a far more consequential choice than its unglamorous reputation suggests. Choose a lab with proven experience in your specific molecule type and matrix, real method development and validation capability, unambiguous regulatory compliance, realistic capacity, and a demonstrated ability to communicate and fix problems fast. Get it right and bioanalysis quietly does its job; get it wrong and you may find yourself questioning data you have already built decisions on.
Method transfer and the study you have not planned yet
An issue that arises more often than sponsors expect is what happens when your bioanalysis needs to move, whether because you change labs, add a second lab for capacity or geography, or take a method in-house. Bioanalytical method transfer is a real technical undertaking: the receiving lab must demonstrate that it can run the method and produce equivalent results, which requires formal cross-validation and takes time. If your program will span multiple studies, regions, or years, thinking about transferability at the outset saves real pain later. Practically, this means favoring labs that document their methods thoroughly and professionally, since a poorly documented method is difficult to transfer and effectively locks you to that lab. It means asking, during selection, how the lab handles method transfer and whether they have done it successfully. It means considering whether you will need bioanalysis in multiple regions, since running samples across borders raises logistical and regulatory complications that a lab with the right footprint can help you avoid. And it means retaining appropriate rights to your methods and data in your contract, so you are not held hostage by a lab that owns the method your program depends on. None of this argues against choosing a single excellent lab, which is often the right answer, but it argues for choosing one whose documentation, professionalism, and contractual terms leave you free to move if you need to. Optionality here costs little to preserve and is expensive to recover once lost.
The bottom line, restated
Bioanalysis is unglamorous, invisible when it works, and catastrophic when it does not, which is exactly why it deserves more attention than it typically gets. Choose a lab with genuinely relevant experience in your molecule type and matrix, real method development and validation capability, unambiguous regulatory standing, honest capacity, and a demonstrated ability to communicate clearly when problems arise. Test their responsiveness before you commit, since how quickly they answer during the sales process is the best available preview of how they will behave when you have an urgent problem at eleven at night before a data deadline.
Visit the lab
If the bioanalysis matters to your program, and it does, visit the lab before you commit. A site visit tells you things no proposal can: whether the facility is orderly, whether the scientists are engaged, whether the quality culture is real or performative, and whether the people who will run your samples inspire confidence. The same instinct that makes sponsors audit their manufacturers applies here, because the data this lab produces will support conclusions you build your program on. An afternoon spent on site is cheap insurance against a year of questioning your own results.
Clarify the timeline in writing
Bioanalysis frequently sits on the critical path, and turnaround times that were verbally reassuring during the sales process have a way of becoming elastic once samples are flowing. Get committed turnaround times into the contract, understand what happens if they slip, and establish clearly what priority your samples have relative to the lab’s other clients. A lab that is unwilling to commit contractually to the timeline they promised verbally is telling you something useful about how reliable that promise was.
Get the contract right
Make sure your bioanalytical contract addresses the things that will matter: committed turnaround, sample ownership and retention, who owns the method, what happens on failed runs, and your rights to transfer the method elsewhere. Bioanalysis contracts are often signed with little scrutiny because the work feels technical rather than commercial, but the terms determine your options if the relationship sours, and being locked to a lab you have lost confidence in, with a method you cannot take elsewhere, is a genuinely bad position.
To find bioanalytical labs and contract research organizations, browse the BioMed Nexus CRO directory, and see our related guides on choosing a CRO and the phases of clinical trials.
Frequently asked questions
How do I choose a bioanalytical lab?
Evaluate relevant experience with your specific molecule type and biological matrix, method development and validation capability, regulatory compliance and inspection history, capacity and realistic turnaround, and data quality systems. Be clear first about what you need, small molecule, large molecule, immunogenicity or biomarker assays, and at what regulatory standard, since labs differ enormously.
What does a bioanalytical lab do?
A bioanalytical lab measures your drug in biological samples, quantifying concentration for pharmacokinetics, assessing pharmacodynamic effect, testing for anti-drug antibodies (immunogenicity), and running biomarker assays. This data underpins your program's pharmacokinetic, safety and efficacy conclusions, which makes lab quality far more consequential than its low profile suggests.
What are red flags in a bioanalytical lab?
Be cautious of labs that cannot demonstrate relevant experience with your specific molecule type, vagueness about regulatory compliance or inspection history, unrealistic turnaround promises that suggest corners will be cut, poor responsiveness during the sales process, and any lab that confidently dismisses the difficulty of a genuinely hard analytical problem.
